Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

Gp, The plan is to VOTE OUT the BOD and they will have to develop a transition plan. The logical choice is to put Dr. Hahne in charge, if he wants the job. If PN is no longer the COB and CEO the extravagant compensation plans may end, especially if the present plan is voted down.

The three accomplishments of BPTH reported on 11/6/17 this year have Hahne's fingerprints all over them. Before he was hired on 4/17/17, BPTH dosed one patient (we know of) in the combination Prexigebersen phase II trial. Now we have 18 dosed in 7 months. A review of the press release shows he is truly qualified to run the company.

"HOUSTON, April 17, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of William Hahne, MD, to the newly created position of vice president of clinical research. During his career, Dr. Hahne has developed extensive expertise in the management of oncology and hematology drug trials as well as valuable experience managing regulatory applications in the US, Canada and Europe.


Peter Nielsen, chief executive officer of Bio-Path Holdings, commented, “Dr. Hahne’s experience directing clinical research programs, maximizing product pipelines, and managing medical affairs teams make him a valuable addition to our team. We look forward to leveraging his years of experience as we continue to advance our lead oncology candidate, prexigebersen, in its ongoing Phase 2 study, and our next asset, BP1002, into clinical studies later this year.”

Before joining Bio-Path, Dr. Hahne was a medical consultant for a number of organizations including Voisin consulting, Medimmune, Lion Biotechnologies, Seattle Genetics, Aminex Therapeutics, Therakos, and Celgene Cellular Therapeutics. He held executive positions in clinical research and medical affairs at Celator Pharmaceuticals (now a subsidiary of Jazz Pharmaceuticals), Celsion Corp, and CurGen Corp, during which he was integrally involved in the design and management of oncology clinical trials, development of key opinion leaders, and growth of clinical departments to meet needs of advancing pipelines. Earlier, he worked in various clinical and medical positions of increasing responsibility at Glaxo Inc., Marion Merrell Dow, Hoechst Marion Rousel, and Eisai, Inc. Dr. Hahne earned his BA in chemistry from Grinnell College and his MD from Cornell University. He conducted his residency in general surgery at Emory University Affiliated Hospitals in Atlanta, Georgia."


Dr. Hahne has the experience in clinical trials and drug development that PN can only dream about. I suspect he made the former COO irrelevant. I believe PN is now irrelevant and untrustworthy as the CEO and COB based on the new compensation plan and his failure to raise more funds when the stock price was much higher.

IMO the company confirmed Dr. Hahne's value in the 11/6/17 press release. When else has that much science been accomplished in 7 months by BPTH?



HOUSTON, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the selection of its third drug candidate, BP1003, for the treatment of pancreatic cancer and provided an update on several of its preclinical discovery efforts.

“We are excited about the ways in which we continue to leverage our novel DNAbilize® technology and are particularly pleased to be moving forward toward the treatment of solid tumors,” said Peter H. Nielsen, chief executive officer of Bio-Path Holdings. “As we advance our current drug candidates into additional indications and add new targets, we continue to establish the DNAbilize® platform as a premier RNAi nanoparticle technology for systemic treatment of disease.”

Bio-Path’s third drug candidate, BP1003, targets the Stat3 protein and is currently in preclinical development in a pancreatic patient-derived tumor model. Previous preclinical models have shown BP1003 to successfully penetrate pancreatic tumors and to significantly enhance the efficacy of standard frontline treatments. Bio-Path intends to initiate IND enabling studies of BP1003 in 2018.

BP1002, Bio-Path’s second drug candidate, targets the Bcl2 protein and has demonstrated strong anti-non-Hodgkin’s lymphoma activity in cell lines and in an animal model. The company has completed IND enabling studies and expects to initiate a Phase 1 trial in lymphoma in 2018.

Prexigebersen, Bio-Path’s lead drug compound, targets the Grb2 protein and is currently in Phase 2 development for the treatment of blood cancers. In recently completed preclinical models, prexigebersen effectively penetrated ovarian tumors and has demonstrated clinical benefit both as a monotherapy and in combination with standard frontline therapies. Bio-Path plans to initiate a Phase 1 clinical trial of prexigebersen targeting several solid tumors types in 2018.


The present stock price (IMO) is not a reflection of the science, rather, it is a judgment on PN's tenure as CEO and the BOD's "rubber stamp" approval of his marginal performance and exorbitant compensation. He received compensation of $1.85 million in 2016 for what? Any bonus is a joke.

"Peter H. Nielsen

Executive Compensation

As CEO, CFO, President, Chairman, Director at BIO-PATH HOLDINGS INC, Peter H. Nielsen made $1,851,492 in total compensation. Of this total $456,250 was received as a salary, $140,000 was received as a bonus, $1,255,034 was received in stock options, $0 was awarded as stock and $208 came from other types of compensation. This information is according to proxy statements filed for the 2016 fiscal year."

https://www1.salary.com/Peter-H-Nielsen-Salary-Bonus-Stock-Options-for-BIO-PATH-HOLDINGS-INC.html